Waldheim Pharmazeutika (Austria) files Product License Application (PLA) for HIV-2 confirmatory test
This article was originally published in Clinica
Executive Summary
Waldheim Pharmazeutika (Austria) has filed a Product License Application with the US FDA for Fluorognost HIV-2-IFA, its HIV-2 confirmatory test. Waldheim's managing director of diagnostics, Dr Hermann Mucke, says that trials of over 7,500 kits gave a sensitivity of 100% in West African and Indian HIV-2 seropositive donors and 99.63% in low-risk HIV-negative US blood donors. Specificity in HIV-negative West African disease ward attendants was 99.48% - significantly higher than Western blotting. Dr Mucke claims that indeterminate results, not false positives, were the reason the kit failed to reach 100% specificity.
You may also be interested in...
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
P&G Restores Volume Growth In Beauty, Grooming After Pricing Run
Procter & Gamble reports strong consumer spending in the US and Europe after a 3% increase in product pricing over the past year. Dragging on fiscal third-quarter results, sales of SK-II in China fell 30% for the January-March period, while lower incidence of cough and cold impacted Health Care performance.
BMS Has A Strong Pipeline, But Access Challenges Remain
Bristol Myers Squibb’s head of major markets, Monica Shaw, wants to improve patients’ access to lifesaving therapies. And the group has several new products ready to roll.